

GENZYME 2009 GUIDANCE

DESCRIPTION	2009 Revised Guidance		Original
	Ranges		
Genetic Diseases	\$ 2,405	\$ 2,465	
Cardiometabolic and Renal	1,035	1,065	
Biosurgery	540	570	
Hematologic Oncology	370	395	
Other	835	890	
TOTAL REVENUE	\$ 5,150	\$ 5,350	
*GROSS MARGIN	approx.	75%	
*SG&A	approx.	26%	
*R&D	approx.	16%	
Amortization	approx.	(275)	0
Net Interest / Other	approx.	30	
TAX RATE - GAAP	approx.	30%	
*TAX RATE - NON-GAAP	approx.	29%	
GAAP EPS	approx.	\$ 3.38	\$ 3.38
OTHER DISCRETE ITEMS	approx.	(0.36)	0.00
GAAP EPS - SUB TOTAL	approx.	3.02	3.38
AMORTIZATION	approx.	0.00	0.70
FAS123R EXPENSE	approx.	0.50	0.50
*NON-GAAP EPS		3.52	4.58
WTD AVERAGE DILUTED SHARES O/S	280	282	
CAPITAL EXPENDITURES	\$ 600	\$ 650	

This financial guidance, which is provided as part of a press release dated May 6, 2009, is subject to all of the qualifications and limitations described therein. Actual results may differ from these forward-looking statements due to the numerous factors described in the press release.

**Non-GAAP excludes the impact of major IPR&D and FAS123R expense.*

SELECT PRODUCT GUIDANCE:

Cerezyme	\$ 1,250	\$ 1,275
Fabrazyme	560	570
Myozyme	370	380
Mozobil	40	50
Renagel/Renvela	725	735